Aileron Therapeutics Inc. (ALRN)

NASDAQ: ALRN · Real-Time Price · USD

2.11

0.18 (9.33%)

At close: Jan 10, 2025, 9:00 PM

9.33% (1D)

Bid	n/a
Market Cap	45.72M
Revenue (ttm)	134K
Net Income (ttm)	-29.24M
EPS (ttm)	-2.88
PE Ratio (ttm)	-0.7326388888888888
Forward PE	-1.19
Analyst	n/a

Ask	n/a
Volume	63,394
Avg. Volume (20D)	101,120
Open	1.97
Previous Close	1.93
Day's Range	1.96 - 2.17
52-Week Range	1.61 - 7.42
Beta	2.34

About ALRN

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine,...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 29, 2017

Employees 15

Stock Exchange NASDAQ

Ticker Symbol ALRN

Website https://www.aileronrx.com

Full Company Profile

Why Price Moved

5 months ago

-13.29%

Aileron Therapeutics shares are trading lower. The... Unlock content with Pro Subscription

8 months ago

-10.81%

Aileron Therapeutics shares are trading lower after the company reported worse-than-expected Q2 EPS results.

News

11 months ago · zacks.com

Down -36.29% in 4 Weeks, Here's Why Aileron Therapeutics (ALRN) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Aileron Therapeutics (ALRN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stree...

2 years ago · zacks.com

Bears are Losing Control Over Aileron Therapeutics, Inc. (ALRN), Here's Why It's a 'Buy' Now

After losing some value lately, a hammer chart pattern has been formed for Aileron Therapeutics, Inc. (ALRN), indicating that the stock has found support. This, combined with an upward trend in earnin...

2 years ago · zacks.com

Aileron Therapeutics, Inc. (ALRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Aileron Therapeutics, Inc. (ALRN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agr...

2 years ago · zacks.com

What Makes Aileron Therapeutics, Inc. (ALRN) a New Buy Stock

Aileron Therapeutics, Inc. (ALRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 years ago · zacks.com

Aileron Therapeutics, Inc. (ALRN) Moves to Buy: Rationale Behind the Upgrade

Aileron Therapeutics, Inc. (ALRN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 years ago · pennystocks.com

Penny Stocks to Buy on August 8th? 3 to Watch

Here's what you need to know about buying penny stocks on August 8th The post Penny Stocks to Buy on August 8th? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennySt...

2 years ago · pennystocks.com

How to Trade Penny Stocks in August 2022

What you need to know about trading penny stocks in August The post How to Trade Penny Stocks in August 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.